Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Budesonide + Formoterol
Symbicort
Routinely available
SMC (SMC2622)
07/08/2024
Indication
As reliever therapy for adults and adolescents (12 years and older) with mild asthma. SMC restriction: for use in patients who would otherwise receive low dose inhaled corticosteroid (ICS) maintenance therapy plus short-acting beta-2 adrenoceptor agonist (SABA) as needed.
Therapeutic Area
Respiratory system
Status Description
Routinely available in line with national guidance
Formulation
200 micrograms/6 micrograms/inhalation, inhalation powder